To understand how neoplastic cells adapt to stresses commonly encountered in solid and hematopoietic malignancies, it is critical to establish how cells alter their metabolism in order to survive these stresses. The purpose of the Metabolism Core is to provide support to the Project Leaders for analyses of cellular metabolism under specific stresses that reflect the unique features of tumor environments: specifically, growth factor withdrawal, nutrient and/or oxygen depletion. The core will provide advice, training, and access to equipment and reagents essential to these inquiries. The core will provide assistance with assays for glucose uptake, glycolysis, NADH and NADPH production, oxygen consumption, and mitochondrial function. Many of the proposed experiments also depend on the use of customized work stations and CO2 incubators for cell culture under hypoxic and/ or anoxic conditions. Furthermore, sucrose gradient centrifugation for polysome profiling will be supervised by a research technician within the core. Therefore, the core will maintain and support the following equipment: A. oxymeter, B. fluorometer, C. hypoxia hoods and specialized hypoxia C02 incubators, D. gradient makers and rotors for sucrose gradient centrifugation. Funds for a second oxymeter, and an anoxia workstation capable of achieving O2 levels_<0.01 % O2, are also requested. The core director, Dr. Brian Keith, will supervise a research specialist in these endeavors. Both core personnel have multiple publications in the areas of cellular bioenergetics, hypoxia and metabolism. The goal of this core is to provide equipment shared by all three research programs and train research associates, postdoctoral fellows, graduate students, and technicians in the techniques described.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA104838-10
Application #
8539281
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$117,279
Indirect Cost
$43,185
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Zhang, Ji; Pavlova, Natalya N; Thompson, Craig B (2017) Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J 36:1302-1315
Davis, Jeremy L; Langan, Russell C; Panageas, Katherine S et al. (2017) Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. Ann Surg Oncol 24:1989-1996
Xie, Hong; Simon, M Celeste (2017) Oxygen availability and metabolic reprogramming in cancer. J Biol Chem 292:16825-16832
Rozpedek, W; Nowak, A; Pytel, D et al. (2017) Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways. Curr Mol Med 17:118-132
Gannon, Patrick J; Akay-Espinoza, Cagla; Yee, Alan C et al. (2017) HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via ?-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol 187:91-109
Ricca, Jacob; Turkekul, Mesruh; Barlas, Afsar et al. (2017) Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. Methods Mol Biol 1554:253-262
Sands, Stephen; Ladas, Elena J; Kelly, Kara M et al. (2017) Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Support Care Cancer 25:701-708
Gade, Terence P F; Tucker, Elizabeth; Nakazawa, Michael S et al. (2017) Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology 283:702-710
Palm, Wilhelm; Thompson, Craig B (2017) Nutrient acquisition strategies of mammalian cells. Nature 546:234-242
Pytel, Dariusz; Gao, Yan; Mackiewicz, Katarzyna et al. (2016) PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. PLoS Genet 12:e1006518

Showing the most recent 10 out of 113 publications